

Clozapine: processes for prescribing, dispensing, supply and monitoring

Initiation of clozapine:

Use the appropriate checklist to ensure all actions are completed day by day - there is a separate checklist for <u>inpatient</u> and <u>community</u> initiations.

Use the standard supplementary chart for the initial titration up to target dose. Target doses are:

- For female non-smokers: 250 mg per day
- For male non-smokers: 350 mg per day
- For female smokers: 450 mg per day
- For male smokers: 550 mg per day

Then adjust dose according to response and tolerance – BNF maximum daily dose = 900 mg per day.

There are also checklists to follow when a patient is <u>admitted</u> to and <u>discharged</u> from an inpatient ward.

Continuing clozapine:

The Trust is fully responsible for the ongoing prescription, monitoring and supply of clozapine to all patients. Processes for the prescription, monitoring and supply via "one-stop" and other clinic models are below in this document. <u>Break in treatment</u> - avoid missed doses; a break in treatment of >48 hours requires re-starting at 12.5–25 mg per day and retitration (but at a faster rate, using a non-standard supplementary chart). A break of >72 hours also requires a return to weekly blood monitoring. Ask pharmacy / the relevant monitoring service for advice.

<u>Therapeutic Drug Monitoring (plasma</u> level assays)

Trust guidance on the role of TDM in relation to clozapine is on the intranet <u>here</u>. Key points:

- Routine (annual) monitoring of plasma levels is <u>not</u> currently required.
- Checking plasma levels is useful to:
 - Confirm non-compliance.
 - Inform dose adjustment if suboptimal response (after 3-6 months)*;
 - Adjust dose after a change in smoking status, or if co-prescription of an enzyme-inducing or inhibiting drug is unavoidable or desirable*;
 - Diagnose and adjust dose in response to dose-related side-effects or signs of toxicity, particularly if the patient has pneumonia or other serious infection;
 - Inform if anticonvulsant prophylaxis is required with higher doses (>600 mg daily) – recommended at levels >0.6 mg/litre
 - Inform dose reviews and adjustments in older patients who are at higher risk of toxicity*

*aim for plasma levels in the range 0.35-0.50 mg/litre (12 hours post-dose)

Safety monitoring:

Baseline / pre-treatment tests are covered in the initiation checklists – see above The Trust <u>Psychotropic Monitoring Guidelines</u> set out the minimum requirements for on-going monitoring of patients in relation to full blood counts (mandatory), weight, waist circumference, blood lipids, blood glucose (HbA1C), blood pressure, pulse and ECG.

Things to ask or check (using appropriate language/phrasing) whenever you see a patient who is taking clozapine:

- What dose have you been taking? Has anyone told you to change your dose? Have you missed any doses?
- Any changes to your other medication, prescribed or over-the counter?
- Do you smoke? Have you recently stopped or started smoking? [see <u>Trust guidance</u> for advice on what to do]
- How is your bowel function? Any signs of constipation? [see <u>Choice & Medication handy fact sheet</u>]
- Do you drink alcohol or caffeine-containing drinks? If so, how much?
- Any other side-effects?......sedation, hypersalivation, nausea, bed-wetting, reflux/heartburn, palpitations?
- Any fever or other signs of infection, e.g. sore throat?

For each question/response – RECORD, ASSESS RISK & TAKE ACTION as appropriate

NEVER events:

- o NEVER initiate clozapine without a thorough physical health check, including an ECG
- NEVER issue a supply of clozapine to a patient following a confirmed RED blood result
- NEVER ignore the signs & symptoms of potentially life-threatening side-effects such as constipation

Title	Clozapine: processes for prescribing, dispensing, supply & monitoring		
Approved by	Drug & Therapeutics Committee	Date of Approval	27 th May 2021, last amended 22 nd Sept 2022
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024



Table of Contents

	3
Prescribing	4
Is Clozapine indicated & appropriate?	4
Initiation of clozapine in an inpatient setting	5
Initiation of clozapine in a community setting	5
Approval for unlicensed/off-label use	5
Patient education & information provision	5
Initial 6-month prescription	6
Dose changes	7
Renewal of 6-month prescriptions	9
Annual review	
Prescription tracker	
Discontinuation of clozapine	11
Dispensing, supply & monitoring	
Overview	12
Preparation, delivery, receipt & return of clozapine	13
Monitoring & supply at one-stop clinics	
Patient attends, sample obtained and analysed on POCHI:	
 Patient attends, sample obtained and analysed on POCHI: Unable to obtain immediate result: 	14
	14 14
Unable to obtain immediate result:	14 14 23
Unable to obtain immediate result:Lost supplies.	14 14 23 24
 Unable to obtain immediate result: Lost supplies. Transfer between care settings 	14 14 23 24 24
 Unable to obtain immediate result: Lost supplies. Transfer between care settings Admission to TEWV inpatient ward 	
 Unable to obtain immediate result: Lost supplies Transfer between care settings Admission to TEWV inpatient ward Discharge from TEWV inpatient ward 	
 Unable to obtain immediate result:	
 Unable to obtain immediate result:	14 14 23 24 24 24 24 24 25 26
 Unable to obtain immediate result:	14 14 23 24 24 24 24 24 25 26 27
 Unable to obtain immediate result:	14 14 23 24 24 24 24 24 25 26 27 27
 Unable to obtain immediate result:	14
 Unable to obtain immediate result:	

Title	Clozapine: processes for prescribing, dispensing, supply & monitoring		
Approved by	Drug & Therapeutics Committee Date of Approval 27 th May 2021, last amended 22 nd Sept 2022		
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024



Appendix 3: Standard clozapine prescription	35
Appendix 4: Prescription tracker example	
Appendix 5: Dose change communication form	37
Appendix 6: Medication log	
Appendix 7: Quarantine sticker, cupboard notice & log sheet	
Appendix 8: Supplying clozapine to a patient outside of one-stop clinic	41
Appendix 9: Counselling checklist for clozapine patients	43
Appendix 10: Template entries for electronic patient record	44
Appendix 11: Clozapine Task Checklist – Inpatient Admission	45
Appendix 12: Clozapine Task Checklist – Inpatient Discharge / Transfer	46
Appendix 13: Clozapine Annual Review Checklist	47
Appendix 14: Template eVCB	48
Appendix 15: Managing Clozapine Overdose	49
Appendix 16: Summary of roles and responsibilities (inpatient settings)	52
Appendix 17: Summary of roles and responsibilities (community settings)	53

Quality standards for all clozapine caseloads (introduced – August 2022)

These standards will be monitored every 12-18 months and for the first time early 2023.

- 1. **Annual review:** <u>Clozapine Annual Review Checklist</u> completed (or the content of the checklist evident in annual review).
 - a. Process standard: every 12 months for all patients
 - b. Audit standard: within the last 15 months for all patients
- 2. Clozapine on Summary Care Record: Clozapine listed on current Summary Care Record for all patients
- 3. Side Effect Monitoring: <u>GASS for clozapine</u> or other rating scale completed at least once in the last 12 months
- 4. **Bowel monitoring:** Bristol Stool Chart (during constipation counselling) used and recorded at least once in the last 3 months.
- Education & Training: Evidence of completion of appropriate clozapine training / CPD for all clinic staff & clozapine prescribers within last 3 years (TEWV ESR training search "clozapine" course title: 346 Online Clozapine Theory)


Title	Clozapine: processes for prescribing, dispensing, supply & monitoring		
Approved by	Drug & Therapeutics Committee Date of Approval 27 th May 2021, last amended 22 nd Sept 202		
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024



Prescribing

Is Clozapine indicated & appropriate?

(consider for all those prescribed antipsychotic medication)







Initiation of clozapine in an inpatient setting See checklist in <u>appendix 1</u>

Initiation of clozapine in a community setting See checklist in <u>appendix 2</u>

Approval for unlicensed/off-label use

If clozapine is being considered for a patient who has previously stopped treatment due to a RED result (re-challenge), or in whom standard mandatory blood monitoring is unlikely to be achieved (e.g. frail Parkinson's disease), or who has another listed contra-indication, the responsible clinician MUST seek approval for initiation from the CPMS (or relevant monitoring service) in the first instance. This approval should be documented in the electronic patient record (e.g. copy and paste of email). Trust approval should then be sought via the relevant lead psychiatrist or AMD using the single application form.

Initiation for an off-label indication does not need prior CPMS (or equivalent) or Trust approval, but must be notified to CPMS (or equivalent) on the patient registration form. All other requirements of off-label prescribing in <u>Trust guidelines</u> apply, e.g. informed patient consent.

Patient education & information provision

- When clozapine is being considered, to inform consent to treatment, the responsible clinician must arrange for an appropriate clinician (e.g. clinical pharmacist) to discuss all aspects of treatment with the patient and/or carer potential benefits, side-effects and monitoring requirements and provide appropriate level information leaflet(s) from the <u>Choice & Medication website</u>.
- Once the patient has provided consent to treatment, the same clinician (ideally) should go through the C&M patient information with the patient and particularly bring their attention to the following key points:
 - AVOID MISSING DOSES if doses are not taken for >48 hours, treatment will need to be restarted at low dose
 - AVOID DRINKING ALCOHOL will enhance any drowsiness caused by clozapine; too much alcohol can be dangerous; tell somebody if alcohol consumption increases
 - AVOID EXCESSIVE CAFFEINE-containing drinks may increase the effects of clozapine; tell somebody if caffeine intake changes (increase or decrease)
 - SMOKING tell somebody if you start or stop smoking, this will affect clozapine levels and dose may need to be adjusted
 - > CONSTIPATION tell somebody if you can't poo, or have stomach pains or feel sick
 - FEVER tell somebody if you get an unexpected fever, sore throat or other flu-like symptoms

A record of the above discussion and provision of information to the patient/carer must be documented in the electronic patient record, including any questions asked and the responses given.

Title	Clozapine: processes for prescribing, dispensing, supply & monitoring		
Approved by	Drug & Therapeutics Committee Date of Approval 27 th May 2021, last amended 22 nd Sept 2022		
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024



Initial 6-month prescription

Following successful titration and dose stabilisation (including adjustment of dose for recommencement of smoking after discharge):

Prescriber:

Notify pharmacy team that an "electronic prescription" for clozapine is now required – by direct contact with a pharmacy staff member and/or email to the relevant dispensary:

- o RPH tewv.pharmacytees@nhs.net
- o WPH <u>tewv.pharmacycdd@nhs.net</u>
- FPH <u>tewv.pharmacyyork@nhs.net</u>

N.B. notify pharmacy staff/dispensary of any "co-meds" that need to be included on this prescription, pending transfer to the GP (where possible)

Clinical Pharmacy Team:

- → Produce an electronic prescription for clozapine (plus any required co-meds) using the template for the relevant locality in the pharmacy <u>shared folders</u> [standard template in <u>appendix 3</u>]. Save the prescription in the relevant clinic folder on the pharmacy shared drive
- → Pharmacist check new prescription is correct against current prescription, i.e. inpatient chart or most recent outpatient prescription
- → **Tees/CDD** copy & paste the prescription into a "Pharmacy" case note on the electronic patient record (EPR) with the statement '*Clozapine prescription sent for checking and signing*'
- → **NYY** print prescription
- → Send prescription to the prescriber for signing via the locally agreed method for that prescriber/clinic, i.e. print & send/hand deliver hard copy OR attach to an email with appropriate password protection* in locally agreed format.
- ightarrow Add patient and prescription details to relevant prescription tracker
- → **Tees/CDD** only check clozapine dose on eVCB and amend if necessary

* 1st password to open as read-only & print (share with prescriber in separate email) + 2nd password for editing (not to be shared with prescriber)

Prescriber:

→ Print (if emailed), check and sign/date prescription; return to pharmacy staff member or directly to relevant dispensary using the most appropriate locally agreed method (e.g. scan & email, via pharmacy drivers, via internal or Royal Mail post).

Dispensary Team:

- → Confirm prescription matches dispensary record of "stable" dose, e.g. copy of inpatient titration chart, copy on EPR (Tees/CDD), latest outpatient prescription pharmacist signs "professional check" box once confirmed
- → **Tees/CDD** add to the existing Pharmacy case note on the EPR, e.g. 'Signed prescription received & professionally checked'.
- \rightarrow **York** copy and paste signed prescription into a Pharmacy case note on the EPR
- ightarrow Update prescription tracker with details of prescription received
- → Check if clozapine and any co-meds are on the patient summary care record if not, email GP practice to request addition
- → Put prescription into <u>dispensing process</u> (N.B. prescription is valid for 6 months from date of <u>first</u> <u>dispensing</u>, not date of signing).

Title	Clozapine: processes for prescribing, dispensing, supply & monitoring		
Approved by	Drug & Therapeutics Committee Date of Approval 27 th May 2021, last amended 22 nd Sept 202		
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024




Dose changes

Prescriber:

When a dose change is needed to clozapine or any "co-meds":

- → Clearly document the required change on the electronic patient record, including the date from when the new dose is to commence
- → Notify pharmacy of the dose change via email to the relevant dispensary, using the communication form in <u>appendix 5</u> (cc'd to any colleagues and specific pharmacy staff who also need to be aware), indicating the urgency of the change:
 - o RPH tewv.pharmacytees@nhs.net
 - WPH <u>tewv.pharmacycdd@nhs.net</u>
 - o FPH tewv.pharmacyyork@nhs.net



Clinical Pharmacy Team:

- → Produce a new electronic prescription with amended dose of clozapine or co-meds using the templates in the pharmacy <u>shared folders</u>. Save the prescription in the relevant clinic folder on the shared drive
- \rightarrow Pharmacist check prescription is correct against prescriber EPR entry and/or email notification.
- → **Tees/CDD** copy & paste the prescription into a "Pharmacy" case note on the EPR with the statement '*Clozapine* prescription sent for checking and signing'; **NYY** print prescription
- → Send prescription to the prescriber for signing via the locally agreed method for that prescriber/clinic, i.e. print & send/hand deliver hard copy OR attach to an email with appropriate password protection
- ightarrow Add prescription details to relevant prescription tracker
- → Tees/CDD only amend clozapine dose on eVCB
- → Suspend current prescription held in dispensary with note, e.g. "new dose change prescription in process"

journey

Prescriber:

→ Print (if emailed), check and sign/date prescription; return to pharmacy staff member or directly to relevant dispensary using the most appropriate locally agreed method (e.g. scan & email, via pharmacy drivers, via internal or Royal Mail post).

Dispensary Team:

- → Confirm dose on prescription matches prescriber EPR entry / email notification of dose change pharmacist to sign "professional check" box once confirmed
- → **Tees/CDD** add to the existing Pharmacy case note on the EPR, e.g. 'Signed prescription received & professionally checked'.
- → **York** copy and paste signed prescription into a Pharmacy case note on the EPR
- ightarrow Update prescription tracker with details of prescription received
- → Check if clozapine and any co-meds are on the patient summary care record if not, email GP practice to request addition
- → Put prescription into <u>dispensing process</u> (N.B. prescription is valid for 6 months from date of <u>first dispensing</u>, not date of signing).

Title	Clozapine: processes for prescribing, dispensing, supply & monitoring		
Approved by	Drug & Therapeutics Committee	Date of Approval	27 th May 2021, last amended 22 nd Sept 2022
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024



Renewal of 6-month prescriptions

Clinical Pharmacy Team:

When the 6-month prescription is due for renewal (either for individual patients ad-hoc or as a batch process for a clinic cohort):

- \rightarrow Check the current Responsible Clinician (RC) this may have changed
- → Check and reconcile the current clozapine dose using two sources of information, e.g. prescription on file and electronic patient record (search case notes for last month to identify any unknown/uncommunicated dose changes)
- → If patient is prescribed "co-meds" access SCR (if patient consent in place) or contact GP practice (if consent to access SCR not granted or unknown) to ensure no duplication of prescribing.
 - o If clozapine not on SCR/GP record email GP practice to add as non-prescribed item
 - o Consider potential transfer of prescribing of co-meds
- → Record details of the clozapine and co-meds reconciliation as a "Pharmacy" case note (not a "medicines reconciliation" case note) on the EPR
- → Produce an electronic prescription for clozapine plus any required co-meds using the templates in the pharmacy <u>shared folders</u>. If SCR checked above, indicate presence/absence of clozapine & co-meds at bottom of prescription. Save the prescription in the relevant clinic folder on the shared drive
- $\rightarrow\,$ If reconciliation done by technician pharmacist to check prescription against the case note entry on EPR
- → **Tees/CDD** copy & paste the prescription into the existing case note on the EPR with the statement '*Clozapine prescription sent for checking and signing*'; **NYY** print prescription
- → Send prescription to the prescriber for signing via the locally-agreed method for that prescriber/clinic, i.e. print & send/hand deliver hard copy OR attach to an email with appropriate password protection* in locally-agreed format.
- \rightarrow Add patient and prescription details to relevant prescription tracker
- → **Tees/CDD** only check clozapine dose on eVCB and amend if necessary
- * 1st password to open as read-only & print (share with prescriber in separate email) + 2nd password for editing (not to be shared with prescriber)

Prescriber:

→ Print (if emailed), check and sign/date prescription; return to pharmacy staff member or directly to relevant dispensary using the most appropriate locally agreed method (e.g. scan & email, via pharmacy drivers, via internal or Royal Mail post).

Dispensary Team:

- → Confirm prescription matches details in Pharmacy case note entry pharmacist to sign "professional check" box once confirmed
- → **Tees/CDD** add to the existing Pharmacy case note on the EPR, e.g. 'Signed prescription received & professionally checked'.
- \rightarrow York copy and paste signed prescription into the existing Pharmacy case note on the EPR
- ightarrow Update prescription tracker with details of prescription received
- \rightarrow Put prescription into <u>dispensing process</u> (N.B. prescription is valid for 6 months from date of <u>first</u> <u>dispensing</u>, not date of signing).

Title	Clozapine: processes for prescribing, dispensing, supply & monitoring		
Approved by	Drug & Therapeutics Committee Date of Approval 27 th May 2021, last amended 22 nd Sept 2022		
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024



Annual review

Every 12 months, in addition to renewing the repeat 6-month prescription, the patient's responsible clinician, or a suitably qualified prescriber in their team, should conduct a full review of the patient and their clozapine treatment according to the checklist in <u>appendix 13</u>. A copy of the completed checklist should be sent to the patient's GP after the review to ensure that the GP/summary care record includes clozapine and any co-meds prescribed by TEWV.

Prescription tracker

See example in Appendix 4

Clinical Pharmacy Team:

- \rightarrow Locate the prescription tracker for the relevant clinic in the individual clinic folder on the Trust Shared Drive (<u>T:\Clozapine</u>)
- → Log a new entry on the prescription amendment tracker whenever a prescription is produced electronically (new prescriptions & dose changes), completing all relevant columns before sending the prescription to the prescriber for signature.

Dispensary Team:

 $\rightarrow\,$ On receipt of a signed prescription, update the prescription amendment tracker "prescription received" columns

Title	Clozapine: processes for prescribing, dispensing, supply & monitoring		
Approved by	Drug & Therapeutics Committee	Date of Approval	27 th May 2021, last amended 22 nd Sept 2022
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024



Discontinuation of clozapine

Clozapine discontinued by prescriber:

Prescriber (ward team if inpatient):

Notify pharmacy team that clozapine has been discontinued via email to the relevant dispensary (cc'd to any colleagues and specific pharmacy staff who also need to be aware):

- o RPH <u>tewv.pharmacytees@nhs.net</u>
- WPH <u>tewv.pharmacycdd@nhs.net</u>
- FPH <u>tewv.pharmacyyork@nhs.net</u>

Clinical Pharmacy / Clozapine Clinic Team:

- → Inform CPMS (or equivalent) of discontinuation <u>CPMS@viatris.com</u>
- → Tees/CDD only update relevant eVCB in dose column enter "discontinuing clozapine" (when patient attends clinic - select "blood monitoring" only in attended column).
- → Ensure post discontinuation bloods are taken at usual frequency for 4 weeks, i.e. if weekly 4 x bloods; two-weekly 2 x bloods; four-weekly 1 x blood or as per instructions from CPMS (or equivalent) if discontinuing due to a red result
- → **Tees/CDD** only once the required post-discontinuation monitoring has been completed, remove the patient from the eVCB

Clinical Pharmacy Team:

- → Move electronic prescription on S drive to a "discontinued/archive" folder*
- → Add comment to the most recent prescription entry on electronic patient record: *"Clozapine Discontinued, Prescription No Longer Valid"*
- * review content of this folder at least annually and permanently delete prescriptions after 12 months

Dispensary Team:

→ Cancel any future issues of medication and file/archive paper copy of prescription (to be stored for 2 years on premises)


Patient deceased:

- Complete relevant notification, removal, and archiving steps as above.
- Whoever notifies CPMS (or equivalent) that the patient is deceased, should notify the relevant dispensary and relevant colleagues when this has been completed.


Title	Clozapine: processes for prescribing, dispensing, supply & monitoring		
Approved by	Drug & Therapeutics Committee	Date of Approval	27 th May 2021, last amended 22 nd Sept 2022
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024



Overview



• The frequency of <u>mandatory</u> blood (FBC) testing is determined by the duration of treatment:



N.B. the duration of weekly or fortnightly monitoring may be extended if amber results occur during these periods

- Patients due to attend each week (1, 2, 3 or 4) are detailed on the specific tab of the clinic eVCB, or equivalent paper folder (in York)
- Notification is sent by CPMS (or equivalent monitoring service) to the relevant dispensary when a patient's monitoring frequency can change - the eVCB / clinic list should be updated accordingly following the "<u>Changes in monitoring frequency/weeks</u>" process. The notification should be forwarded to the relevant RC and care co-ordinator
- Patients are allocated to their nearest local clozapine clinic when newly initiated/discharged or transferred to the Trust; patients can be transferred between clinics following the "<u>Transfer</u> <u>between community clinics/ from in-patient settings</u>" process.
- Medication to be supplied to patients at each clinic, following completion of required monitoring, should be prepared, delivered and stored according to the "<u>Preparation, delivery</u>, <u>receipt & return of clozapine (one stop clinics)</u>" process

Clozapine blood result validity:

The maximum amount of medication that can be supplied from the date of the most recent GREEN blood result is:

Monitoring frequency	Clozaril [®] / Denzapine [®]	Zaponex [®]
Weekly	10 days	14 days
2-weekly	21 days	21 days
4-weekly	42 days	42 days

Title	Clozapine: processes for prescribing, dispensing, supply & monitoring		
Approved by	Drug & Therapeutics Committee	Date of Approval	27 th May 2021, last amended 22 nd Sept 2022
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024



Dispensary Team:

- → If prescription requests a supply greater than the monitoring interval, prepare instalments to be issued in line with the monitoring interval, e.g. 6 weeks requested, 2-weekly monitoring prepare 3 x 2-week instalments
- → Dispense, and prepare for delivery, the medication for each week by the agreed day before the cohort's clinic / blood sampling day
 - Where a non-batch process applies, notify the clinical pharmacy team when the last instalment of a 6-monthly script has been dispensed so that a new script can be produced prior to the next scheduled supply
- → Deliver the medication to the clinic / relevant GP surgery in sealed tamper evident tote boxes, clearly labelled 'Quarantined Clozapine', with a copy of the eVCB (or equivalent in York), and relevant prescriptions

Community team / GP practice staff:

Appropriate team member signs delivery note and places sealed boxes in agreed secure location

Pharmacy Technician (one-stop clinics):

On arrival at the clinic:

- → Check delivery boxes are still sealed. If the seals are broken contact the dispensary team immediately.
- → Check medication against the eVCB (or equivalent) at the start of clinic, notifying the dispensary of any discrepancy immediately.
- \rightarrow Enter quarantined medication onto eVCB (or equivalent) for each patient.
- \rightarrow Transfer medication to quarantine cupboard, or suitable secure location, in a logical manner.
- → Check other medication cupboards on site for any clozapine not collected since previous clinic. If there is any uncollected medication, contact the relevant care coordinator to ascertain reason why not collected and whether any action is required from a break in treatment, i.e. re-titration

Before leaving the clinic:

- → For patients on 4-weekly monitoring with a green result who collect their medication weekly, the remaining 3 weeks' supply should be transferred to the main clinic medicines cupboard, NOT the quarantine cupboard, and an entry made on the medication log sheet. (Appendix 6)
- → Any other medication not issued (i.e. for non-attenders) should be returned to the quarantine cupboard; in the absence of a separate quarantine cupboard this medication should be put into the main medication cupboard with a "quarantined medication" sticker attached (<u>Appendix 7</u>). This medication can be issued according to the "<u>patient fails to attend</u> <u>clinic as scheduled</u>" process.
- → Any returned medication and the file containing the prescriptions should be placed in a suitable, securely sealed container for collection and return to the relevant dispensary on the next pharmacy driver run.



→ The eVCB (or equivalent in York) for each clinic should be checked at an appropriate time each week to follow up any non-issued clozapine for that week.





Monitoring & supply at one-stop clinics

Patient attends, sample obtained and analysed on POCHI:

Clozapine Clinic Team:

- → Follow standard venepuncture procedure take relevant bloods for mandatory FBC monitoring and complete physical health monitoring
- → Follow operating instructions for PoCHi machine, ensure correct patient details selected, confirm blood result (red/amber/green) on CPMS and document details on the eVCB (Tees/CDD/NY) or paper record (York)
- → Perform physical observations as appropriate, recording results on electronic patient record
- \rightarrow Assess patient mental state and presentation, record on electronic patient record

Unable to obtain immediate result:

Patient fails to attend clinic as scheduled:

Pharmacy Technician (in One-stop clinic):

- → Do not release medication
- → If clinic has a cupboard specifically for quarantined clozapine –secure the patient's medication in this cupboard (with a copy of the prescription) until a RAG blood result is obtained
- → If clinic does <u>not</u> have a separate cupboard for quarantined clozapine attach a "Quarantined clozapine" sticker to the outer bag and secure the medication (with a copy of the prescription) in the general medicines cupboard, separate to other medication
- \rightarrow Record details on the "Quarantined clozapine log sheet" (Appendix 7)

Clozapine Clinic Team / Care Co-ordinator:

Contact patient to arrange attendance at clinic or a home visit to obtain a blood sample

Clozapine Clinic Team: once sample has been obtained....

- → If possible, analyse sample on PoCHi machine; if not possible, follow alternative process (see below) to obtain & document the blood result
- \rightarrow Contact relevant dispensary to request authorisation to release quarantined clozapine

Dispensary Team (Pharmacist or Pharmacy Technician):

 \rightarrow Check for RAG blood test result on CPMS – if GREEN, supply code to release the key for the quarantine cupboard and/or permission to release quarantined medication to the patient

 \mathbf{V}

Under no circumstances should the supply be released in the absence of a valid blood result

→ Make a case note entry on the electronic patient record recording permission for release from quarantine & notify the clinic pharmacy technician to record on eVCB

Title	Clozapine: processes for prescribing, dispensing, supply & monitoring		
Approved by	Drug & Therapeutics Committee	Date of Approval	27 th May 2021, last amended 22 nd Sept 2022
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024



Clozapine Clinic Team / Care Co-ordinator (qualified nurse):

- ightarrow Record the name of authorising pharmacy staff on the quarantine cupboard log
- → If a "Quarantined clozapine" sticker is attached, attach a "Green result" sticker covering the "quarantined" sticker".
- \rightarrow Check the following prior to handing medication to patient:
 - Patient name
 - Whether they still have any medication at home in excess of their validity
- \rightarrow Ask patient to sign for receipt on the "quarantine cupboard log sheet"
- → Counsel patient as appropriate (See <u>Appendix 8</u>) refer to another clinician/pharmacist when necessary
- \rightarrow Ensure patient knows the date of their next blood test/clinic appointment

Unable to obtain sample/sufficient sample

- Check if any other phlebotomy trained staff are available on-site to obtain required sample.
- If not, make alternative arrangements to access phlebotomy services elsewhere e.g. local hospital or GP then follow process <u>below</u>.

Unable to analyse sample

- **T2 error on PoCHi machine Allow** sample to settle for 2 minutes, re-mix sample on mixer and re-run sample **ONCE** only. If T2 error still occurs, follow process on next page.
- **PoCHi failure** PoCHi machine not working, or stops working during clinic, contact CPMS / Sysmex and follow process on next page.
- **Patient prescribed a brand other than Clozaril**[®] PoCHi machine can't be used, follow process on next page.

Title	Clozapine: processes for prescribing, dispensing, supply & monitoring		
Approved by	Drug & Therapeutics Committee	Date of Approval	27 th May 2021, last amended 22 nd Sept 2022
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024



If an immediate result is not available for whatever reason, the following steps should be followed:

Clozapine Clinic Team:

- → Discuss with/explain to patient reasons for being unable to obtain a result within one stop clinic.
- → Follow locally agreed route for analysis of sample, this may involve posting to CPMS or sending to local pathology laboratory; this will also depend on sampling frequency and previous blood result validity
- → Check with patient the length of supply remaining in their possession & ascertain whether a further supply will be needed to cover the period until the result is available (this will depend on/determine where the blood sample has been/should be sent).
- → Inform dispensing pharmacy that a result is not available obtaining advice regarding the number of days of medication supply allowed, taking into account blood result validity

Pharmacy Technician (One-stop clinic):

- → If possible, supply partial medication as determined above, document amount supplied on electronic patient record and quarantine any remaining supply.
- → If the "one-stop" medication cannot be used for a partial supply, e.g. in a compliance aid, return it to the quarantine cupboard or the relevant dispensary.

Clozapine Clinic Team:

- → Agree with patient/clinical staff how full or remainder of medication supply will be collected or delivered from community clinic once result is obtained
- → If sample sent to local pathology laboratory, a clinical team member should be nominated to retrieve the result via the electronic patient record and enter it onto the CPMS system (or email/telephone CPMS@viatris.com, 0845 7698269)
- → Proceed according to the result on CPMS (Red / Amber / Green)
- → If partial supply given, arrange with relevant dispensary/clinical pharmacy team for appropriate supplementary supply to be prepared.
- → If full quarantined one-stop medication to be used, follow steps for release in "<u>patient</u> <u>fails to attend</u>" process

Dispensary Pharmacy Team:

Title

Appro

Protoc

→ Once result obtained, release medication from quarantine (one-stop – follow process outlined in "patient fails to attend") or directly from dispensary if providing a supplementary supply to re-align supplies to next clinic week.

Clozapine Clinic Team / Care Co-ordinator:

- → If the quarantined one-stop medication supply is used, follow steps for release in "<u>patient</u> <u>fails to attend</u>" process
- → Ensure patient receives their supply of clozapine and next clinic appointment



Result obtained and responses to safety questions recorded on electronic patient record & eVCB (or equivalent)

Smoking status

Clozapine Clinic Team:

At every clinic attendance check each patient's smoking status & record on their electronic patient record:

- \rightarrow If there is no change to smoking status, take no further action.
- → If smoking status has changed, clarify when the patient stopped / started smoking & notify consultant / care co-ordinator so that an early review can be arranged.

Prescriber/Clinician:

→ Refer to "Stop Smoking Products" guidelines and/or "Clozapine and the role of therapeutic drug monitoring" guidelines (via Intranet) to determine whether a check of plasma clozapine levels is appropriate & notify clozapine clinic team of any action needed

 $\mathbf{1}$

Title	Clozapine: processes for prescribing, dispensing, supply & monitoring		
Approved by	Drug & Therapeutics Committee	Date of Approval	27 th May 2021, last amended 22 nd Sept 2022
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024



Clozapine plasma level requested by RC (or appropriate clinician):

- This is <u>not</u> a routine or mandatory blood test that can be completed in the one-stop clinic
- A plasma level assay is only done if clinically indicated, e.g. to assess compliance*, to help assess poor response or dose-related side-effects, to monitor the effect of changes in smoking habit – see "<u>Clozapine & the role of Therapeutic Drug Monitoring guidance</u>".
- While the blood sample for a plasma level assay may be taken in the one-stop clinic, it cannot be analysed on the PoCHi machine or at the local hospital path lab it must be sent to the commissioned external specialist laboratory (currently Viapath)
- The result of a plasma assay is reported after 3-5 days as a "level" in mg per litre (mg/L) not as red/amber/green (this terminology is only used in relation to the routine, mandatory FBC monitoring)

*the result of the plasma level assay (clozapine vs norclozapine levels) will indicate if there has been non-compliance or poor compliance with the prescribed dose in the preceding few days, regardless of the patient's self-reported compliance.

Clozapine Clinic Team:

- → Contact patient and advise to omit morning dose (if applicable) on day of next clinic visit
- \rightarrow At clinic visit, draw additional blood sample (within 12 hours of last dose); complete plasma clozapine assay request form, check time last dose taken & smoking status
- ightarrow Pack in envelope/packaging provided & post to relevant laboratory for analysis
- $\rightarrow\,$ Record blood sampling and purpose on electronic patient record
- \rightarrow Advise patient to take omitted morning dose (if applicable) as soon as possible

Clinical Pharmacist / Pharmacy Team / Care co-ordinator:

When email notification of a plasma clozapine level is received:

- \rightarrow Access relevant online results gateway
- ightarrow Copy and paste result into electronic patient record
- → Notify RC/appropriate clinician of level by most appropriate route (dependent on urgency) and agree any action required


Prescriber / appropriate clinician (inc.pharmacy team):

- → Review plasma level result (refer to Trust "Clozapine & the role of therapeutic Drug Monitoring Guidance")
- \rightarrow Amend dose of clozapine if necessary & arrange for new prescription if dose is changed
- $\rightarrow\,$ Document actions on electronic patient record
- → Re-check plasma levels one week after dose change & until clinical indication for checking levels has resolved (e.g. resolution of side-effects, compliance confirmed)

Title	Clozapine: processes for prescribing, dispensing, supply & monitoring		
Approved by	Drug & Therapeutics Committee	Date of Approval	27 th May 2021, last amended 22 nd Sept 2022
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024



Red Result



Clozapine Clinic Team:

- \rightarrow Inform RC, care co-ordinator, ward team (if inpatient) and relevant dispensary of RED result
- → Tell patient to **STOP** taking clozapine **IMMEDIATELY**. If patient is not present at time of result, agree who will contact them.
- → Contact CPMS (or other monitoring service where relevant) for advice regarding further blood testing & share this information with the RC, care co-ordinator, ward team (inpatients) and relevant dispensary
- → Ensure further monitoring is completed as per CPMS instruction until advised that it can cease (ongoing frequency may vary depending on actual results)
- → Update eVCB or equivalent (York)


Person identified to contact the patient:

- \rightarrow Inform the patient that they must STOP taking clozapine IMMEDIATELY
- → For in-patients ensure clozapine discontinued on prescription & administration record chart
- → For community patients arrange retrieval of all supplies of medication held by the patient and return any medication to relevant Trust dispensary using secure transport
- \rightarrow Check with the patient to see if they are experiencing any signs of infection e.g. sore throat
- \rightarrow Ensure blood sampling is undertaken in accordance with CPMS advice
- → If **RED** result is received out of hours follow advice above & arrange which staff will retrieve further blood results, ensuring arrangements are made for the next blood test. (If staff member retrieving result out of hours is unable to access CPMS, contact on call pharmacist to have results entered onto CPMS, results must be reported as soon as they are available).

Title	Clozapine: processes for prescribing, dispensing, supply & monitoring		
Approved by	Drug & Therapeutics Committee	Date of Approval	27 th May 2021, last amended 22 nd Sept 2022
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024



Red Result actions:



Footnotes:


- 1. Sudden cessation of treatment with clozapine can lead to physical & mental withdrawal effects which may occur within 2-3 days, usually within the first two weeks. Patients may experience a rapid deterioration in their mental state with rebound psychosis. Abrupt withdrawal of clozapine has also been associated with symptoms such as nausea, vomiting, diarrhoea, headache, restlessness, agitation & sweating.
- 2. Following a RED result, daily blood monitoring must be completed for at least TWO days, if either of these two results is RED, this is a confirmed RED result & the patient is non-challengeable with clozapine. If the second result is AMBER or GREEN, the third daily test must still be completed. This means that a red result will almost always necessitate re-titration of clozapine as the patient will have a treatment break of >48 hours.
- **3.** Clozapine can be re-titrated if a patient does not get a second RED result, but this should be a clinical decision & must be discussed with the appropriate monitoring service.

Title	Clozapine: processes for prescribing, dispensing, supply & monitoring		
Approved by	Drug & Therapeutics Committee	Date of Approval	27 th May 2021, last amended 22 nd Sept 2022
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024



Amber result

Tees, Esk and Wear Valleys



Appro	ttee	Date of Approval	27 th May 2021, last amended 22 nd Sept 2022
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024



Tees, Esk and Wear Valleys

GREEN result obtained on PoCHi machine or via local pathology lab or CPMS

Pharmacy Team (One Stop Clinic or Dispensary):

→ Enter the blood test date and result on the supply log on the prescription and initial (this should be done BEFORE medication is issued to ensure medication is not given out before blood result is received).

Medication can be released to the patient after checking the following against the CPMS (or equivalent) record & the prescription:

- Patient's name
- Patient's date of birth
- CPMS (or equivalent) number
- Dose of each medication
- Whether the dose has been changed by anyone, including the patient, since the last supply of medication
- Whether the patient has missed any doses recently
- Whether patient only collects one week of medication at a time due to compliance issues
- Check the amount remaining from previous supply this should not exceed the amount needed until the end of the current blood testing week, i.e. a rolling excess of 3-4 days' supply (excluding any buffer supplied for business continuity purposes)
- Counsel patient as appropriate see <u>Appendix 9</u> (One-stop clinic) or <u>Appendix 8</u> (Dispensary/community team)

Refer to pharmacist/RC/care co-ordinator/clozapine clinic team when necessary depending on responses to questions above

- \rightarrow A standard minimum entry must be made on the electronic patient record (<u>Appendix 10</u>) and any additional information should be added as necessary.
- \rightarrow Update the eVCB (or equivalent) and arrange the next appointment

Title	Clozapine: processes for prescribing, dispensing, supply & monitoring		
Approved by	Drug & Therapeutics Committee	Date of Approval	27 th May 2021, last amended 22 nd Sept 2022
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024





Lost supplies

Reported by patient/carer

- If a patient/carer reports that a supply of clozapine has been lost the priority must be to consider how missed doses can be avoided such that re-titration is unnecessary (doses missed >48 hours). This will usually require an interim/emergency supply while the loss is investigated.
- In working hours contact the usual supplying Trust dispensary and agree a quantity to be ordered/supplied, taking into consideration:
 - The risk of overdose or diversion (if the reported loss is potentially false)
 - \circ $\;$ The validity of the most recent blood result / date of next clinic visit
 - The capability of the patient to collect or team to deliver further interim supplies until next full supply
- Out of hours contact on-call pharmacist and refer to "<u>Clozapine: Process for accessing out of hours</u>"
- Once an emergency supply has been arranged and missed doses avoided, the clinical team should investigate the validity and circumstances of the loss and report it as a medication incident on Datix and in the EPR, including the following details:
 - How many days' supply (approx.) were there?
 - \circ Where the supply was lost / last in the patient's possession?
 - What has the patient/carer done to try and find it?
 - Was any other medication lost with it?
 - Has this happened before with this patient?
- Consider any risk to:
 - Patient loss of symptom control from missed doses; any safeguarding concerns?
 - Family any risk of accidental ingestion by children if lost at home?
 - Public (e.g. if left on a bus) has it been reported to bus company?
- If repeat incident, review capability of patient to manage current supply arrangements are weekly supplies required (within 2-weekly / 4-weekly monitoring)?

Reported by inpatient ward

- If a ward reports that a supply of clozapine for a particular patient has been lost the priority
 must be to consider how missed doses can be avoided such that re-titration is unnecessary
 (doses missed >48 hours). This will usually require an interim/emergency supply while the loss
 is investigated.
- In working hours contact the usual supplying Trust dispensary and agree a quantity to be ordered/supplied, taking into consideration the validity of the most recent blood result / date of next clinic visit
- Out of hours refer to "<u>Clozapine: Process for accessing out of hours</u>"
- Once an emergency supply has been arranged and missed doses avoided, the ward team should investigate the loss and report it as a medication incident on Datix
- If repeat incident on this ward, review arrangements for safe medicines storage and management of patient-specific supplies

Title	Clozapine: processes for prescribing, dispensing, supply & monitoring		
Approved by	Drug & Therapeutics Committee	Date of Approval	27 th May 2021, last amended 22 nd Sept 2022
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024



Transfer between care settings

Admission to TEWV inpatient ward See checklist of admission tasks in <u>appendix 11</u>

Discharge from TEWV inpatient ward See checklist of discharge tasks in <u>appendix 12</u>

Transfer between clinics / inpatient to clinic / from another Trust

Departing Clozapine Clinic Team:

Notify relevant dispensary of patient transfer – including all relevant patient details, any comments from eVCB (or York equivalent) and any outstanding monitoring or supply issues, e.g. waiting for plasma levels

Departing Clinical Pharmacy Team:

Remove patient from eVCB (or York equivalent) and update electronic patient record using a standard pharmacy case note entry

Receiving Clinical Pharmacy Team:

- $\rightarrow\,$ Inform monitoring service of any changes in consultant, blood sampling venue, dispensing pharmacy, etc.
- → Add patient to receiving clinic eVCB (or York equivalent) updating details & electronic patient record using a standard case note entry

Receiving Clinical Pharmacy team:

- \rightarrow Internal transfer:
 - \circ $\,$ update the site & consultant details (if required) on the electronic prescription template
 - o check if any comments are still relevant
 - ensure that dispensing pharmacy details are amended in the footer of the script or transfer to the dispensary-specific prescription template
- $\rightarrow\,$ Transfer from another Trust generate new prescription with details provided by departing Trust
- ightarrow Save updated / new prescription in relevant pharmacy shared folders

Title	Clozapine: processes for prescribing, dispensing, supply & monitoring		
Approved by	Drug & Therapeutics Committee	Date of Approval	27 th May 2021, last amended 22 nd Sept 2022
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024



Emergency supply for non-TEWV patient

- On rare occasions it may be necessary to arrange an emergency supply of Clozapine to a patient from another Trust (e.g. a holidaymaker who has forgotten to bring their own supply, or admitted to a TEWV inpatient unit)
- CPMS and the other Clozapine monitoring services have a "Memorandum of Understanding" that such a supply may be made under these conditions to ensure continuity of treatment. If more than 7 days' supply is required, the patient must be registered with the relevant monitoring service before further supplies may be made

Prescriber (e.g. Crisis Team):

- → Contact home Trust/team and confirm patient details (name, DOB, NHS number and monitoring service number) with medical or nursing staff
- \rightarrow Check the current "blood status" with the appropriate blood monitoring service:
 - Clozaril[®] CPMS 0845 7698269 or <u>CPMS@viatris.com</u>
 - Zaponex[®] ZTAS 0207 3655842 Mon-Fri 9am-5pm only
 - Denzapine[®] DMS 0333 2004141
- → Issue a prescription for a maximum of 7 days of Clozaril[®] if all facts validated and a current **GREEN** blood result valid for the prescribing period is in place
- → Inform the relevant Trust dispensary to expect the prescription (NB. can't be dispensed by a community pharmacy)

Dispensary Team:

- \rightarrow Issue up to 7-day supply of medication as per prescription
- → Ensure prescriber is aware of arrangements needed to enable further supplies where relevant

Title	Clozapine: processes for prescribing, dispensing, supply & monitoring		
Approved by	Drug & Therapeutics Committee	Date of Approval	27 th May 2021, last amended 22 nd Sept 2022
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024



Elective admission - patients should ensure their current own supply of Clozapine is taken into hospital with them.

Emergency admission:

Whichever TEWV team is informed of admission e.g. Liaison Team:

<u>Notify</u> the relevant clozapine clinic team / dispensary that the patient has been admitted and their current location

Clozapine Clinic Team / Care Co-ordinator:

Arrange for standard monitoring of FBC / pick up admission blood results as appropriate and ensure result is entered onto CPMS

Dispensary Team:

- → Issue 7-day supplies of medication as needed (from current 6-month prescription if valid or request a new handwritten prescription)
- → Transfer medication to Acute Trust using whichever method of supply is most appropriate at the time, using scheduled delivery runs if possible & maintaining an audit trail
- \rightarrow Establish communication with acute Trust pharmacy team to arrange further supplies

See: <u>Safety guidance - Clozapine on admission to an acute hospital ward - Tees Esk and Wear Valley</u> NHS Foundation Trust (tewv.nhs.uk)

N.B. a small supply of clozapine 25 mg and 100 mg tablets is held in the emergency cupboard at York District Hospital, but not at any other acute hospital within the TEWV footprint

Title	Clozapine: processes for prescribing, dispensing, sup	ply & monitoring		
Approved by	Drug & Therapeutics Committee	Date of Approval	27 th May 2021, last amended 22 nd Sept 2022	
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024	



Miscellaneous processes

Changes in monitoring frequency / weeks

Dispensary Team:

→ Receive email from relevant monitoring service authorising change in monitoring frequency

↓

 \checkmark

- \rightarrow Determine which clinic patient attends
- \rightarrow Notify relevant pharmacist/technician

Clinical Pharmacist / Pharmacy Team:

Update eVCB (or equivalent in York) & electronic prescription

Clozapine Clinic Team:

Notify patient & Care Co-ordinator of the change & next clinic appointment

Title	Clozapine: processes for prescribing, dispensing, supply & monitoring				
Approved by	Drug & Therapeutics Committee	Date of Approval	27 th May 2021, last amended 22 nd Sept 2022		
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024		



Notification of any changes to treatment



Prescriber:

Notify the relevant dispensary via email:

- When a patient has reached a maintenance dose of Clozapine
- When there are any dose changes of Clozapine.
- If a co-med has been started or stopped or a dose has changed.

Any changes must also be recorded as a case note on the electronic patient record

- \rightarrow Select the appropriate dispensary email address:
 - o RPH <u>tewv.pharmacytees@nhs.net</u>
 - WPH <u>tewv.pharmacycdd@nhs.net</u>
 - FPH tewv.pharmacyyork@nhs.net
- \rightarrow Cc to any clinical colleagues or specific pharmacy staff who need to be aware
- → Entitle the email "Clozapine/Co-med dose change" <u>do not</u> use patient details within the title field
- \rightarrow Within the body of the email include:
 - Electronic patient record ID
 - Date of relevant electronic patient record entry
 - Required start date of any dose changes (if non-urgent, default will be next clinic date)

Clinical Team member:

A notification should be sent to the relevant dispensary

- When a new patient is initiated on clozapine or transferred to TEWV on clozapine
- When there is a change in monitoring frequency
- When there is a change in monitoring setting e.g. change of community clinic, discharge from in-patients
- Where a patient is admitted to hospital e.g. acute Trust
- To share any other relevant information
- \rightarrow Select the appropriate dispensary email address:
 - o RPH <u>tewv.pharmacytees@nhs.net</u>
 - o WPH <u>tewv.pharmacycdd@nhs.net</u>
 - o FPH <u>tewv.pharmacyyork@nhs.net</u>
- \rightarrow Cc to any clinical colleagues or specific pharmacy staff who need to be aware
- \rightarrow Entitle the email "Clozapine notification" <u>do not</u> use patient details within the title field
- ightarrow Within the body of the email include
 - Electronic patient record ID
 - Date of any relevant electronic patient record entry

	Title	Clozapine: processes for prescribing, dispensing, supply & monitoring				
ſ	Approved by	Drug & Therapeutics Committee	Date of Approval	27 th May 2021, last amended 22 nd Sept 2022		
	Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024		



Clozapine eVCB

(Not applicable in York)



eVCB MUST be saved at the end of EVERY step. NEVER save a copy

Make changes/add patients to the eVCB:

Clinical Pharmacy Team:

- \rightarrow Access Clinic eVCB on the T drive <u>T:\Clozapine</u> & enter relevant passwords to open the excel spreadsheet
- \rightarrow To make changes e.g. add patients or move patients between clinic weeks
 - Click on the "review" tab at the top of the spreadsheet & select "unprotect sheet".
 - A box will appear, type the sheet protection password in, to unlock the sheet for editing.
 - Enter all patient demographics in the relevant columns
 - Once editing is complete, go back to the "review" tab & select "protect sheet"
 - A box will appear, enter the password used to unlock the sheet.
 - Another box will appear & ask you to reconfirm the password.
 - Enter the password in the same format.
 - Take care not to change the password when you re-enter it. If you make any changes you will create a new password & all users must be informed.
 - If you change & forget the password, you will not be able to unlock the sheet in the future contact IT if locked
- \rightarrow Click on the "save" button to save any changes

Update dispensing information on eVCB:

Dispensary Team:

- \rightarrow Access Clinic eVCB on the T drive <u>T:\Clozapine</u> & enter relevant passwords to open the excel spreadsheet
- \rightarrow Complete column headed Dispensed (Yes/No).
- \rightarrow Complete quarantine column for clinics without a one-stop facility (Yes/No)
- Note: these columns link to the date of clinic column

Update medication quarantine information (one stop clinic):

Pharmacy Technician (One Stop Clinic):

- → Access Clinic eVCB on the T drive <u>T:\Clozapine</u> & enter relevant passwords to open the excel spreadsheet
- → After medication has been checked and quarantined in agreed area, update quarantine column. If any medication is missing contact the relevant dispensary and make arrangements for medication to be delivered.

Note: quarantine column links to date of clinic column

Title			
Approved by	Drug & Therapeutics Committee	Date of Approval	27 th May 2021, last amended 22 nd Sept 2022
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024



Add to/update eVCB during one stop clinic:

Clozapine Clinic Team:

- \rightarrow If not already open access Clinic eVCB on the T drive <u>T:\Clozapine</u> & enter relevant passwords to open the excel spreadsheet
- \rightarrow Complete clinic date column
- → For each patient, enter details in "Attended" column and "Blood Status" column, selecting the relevant options for the patient from the lists.
- \rightarrow Make appropriate entries on the electronic patient record
- \rightarrow Notify red or amber result to clinical team as per relevant process
- → Inform pharmacy teams if blood sample or blood result is unobtainable for any reason as per relevant process
- → At the end of the clinic change 'Clinic Date' column after each weekly clinic to the date when the next clinic is due in its rotation

Update issue of medication to patient at one stop clinic:

Pharmacy Technician (One Stop Clinic):

- \rightarrow eVCB should already be open
- → If blood and physical monitoring is within correct guidelines, (i.e. Green Blood Result) release medication to patient
- → Complete "clozapine released" column
- → Report any delays in collection of medication to the Care Coordinator (obtain current details from electronic patient record)
- \rightarrow After the clinic is finished, complete any follow up work as necessary

Update issue of medication to patient from dispensary:

Dispensary Team:

- \rightarrow Access Clinic eVCB on the T drive <u>T:\Clozapine</u> & enter relevant passwords to open the excel spreadsheet
- \rightarrow If blood & physical monitoring is within correct guidelines, (i.e. Green Blood Result) release medication to patient.
- \rightarrow Complete "clozapine released" column
- → If blood results are delayed and a subsequent valid Green result is reported fill in details of release date and initial in column "Released (pharmacy staff initials)" when clozapine is released from quarantine
- → Report any delays in collection of medication to the Care Coordinator (obtain current details from electronic patient record)
- $\rightarrow\,$ At the end of each week, reset the Dispensed and Clozapine Quarantined columns to "No" for all patients.

Title	Clozapine: processes for prescribing, dispensing, sup	oly & monitoring		
Approved by	Drug & Therapeutics Committee	Date of Approval	27 th May 2021, last amended 22 nd Sept 2022	
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024	



Appendix 1: Clozapine Task Checklist – In-patient initiation

Patient Name:	Date of Birth:	NHS No:
Ward:	Consultant:	CPMS No.:

Note: CPMS = CPMS or equivalent monitoring service (ZTAS or DMS)

✓					Initial	Date
	MDT decision made to c	ommence clozapine with patie	nt consent* or in line	e with		
	MHA consent to treatme	nt requirements (*if off-label use	, ensure consent cove	ers this)		
	document on electronic asked	patient re potential benefits, mo patient record, including inform	ation provided & qu	estions		
		s are completed and results re Ith case note - <i>inform doctor o</i>				
	Physical examination	Weight (W)	U&Es			
	Blood pressure	Calculate weight	Lipids			
	Temperature	increase threshold (W x 1.05) =	Prolactin			
	Pulse	Waist circumference	HbA1c			
	Height	ECG	LFTs			
	from sample date	sent to local Path Lab – this w	ill only be valid for a	IU days		
	Confirm consultant regis					
		eam of intention to commence	<u> </u>			
		completed and sent to CPMS		_,		
		on and green result from CPM nple so clozapine must comme				
	Prescribe clozapine on p titration chart'	rescription and administration	record with dose 'a	s per		
	Prescribe clozapine on g	reen titration chart (either star	dard or individualis	ed)		
	Order initial supply of clo	zapine from dispensary using	one of the following	options:		
		scan/email signed titration cha original returned to ward)	rt to dispensary (co	py will be		
		atient order on EMIS after clini	cal check by pharm	acist		
ST	EP 2: COMMENCEME	NT OF CLOZAPINE, DAY	1:			
 ✓ 		, ,			Initial	Date
	Immediately prior to adm	inistration of clozapine assess	NEWS and record	on chart		
		within normal limits administer				
		octor for advice as to whether o	clozapine can be			
	administered If first dose taken at nigh	t no further monitoring require	d that day			
	-	the day NEWS parameters to		or six		
		patient record: Significant mec	lication alert – patie	nt on		

Title	Clozapine: processes for prescribing, dispensing, supply & monitoring				
Approved by	Drug & Therapeutics Committee	Date of Approval	27 th May 2021, last amended 22 nd Sept 2022		
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024		



all le				IE, DAYS 2 – 1 4 essarily in order lis						
									Initial	Date
		nple obtained fo days of baselin		sent for analysis	Pochi mach	ine or path	ı lab)			
		•		nce daily (ideally	2-6 hours po	st-dose) a	nd infor	m		
	medical s	taff if paramete	rs out of rar	nge	-	-				
	Day 7 & o record	day 14 – check	weight and	record on prescrip	otion chart ar	nd electror	nic patie	nt		
		iscuss the following common side effects with patient and record presence/absence electronic patient record each week Constipation Sedation Hypersalivation Nocturnal enuresis Nausea Signs of infection								
		Constipation	Sedation	Hypersalivation		Nausea				
	Week 1									
	Week									
	2									
				s an increase in si				ng		
				mpleted including		•				
	EP 4: ST	ABILISATION	OF CLOZ	APINE THERA	PY, DAY 1	5 ONWA	RDS:		[_
·	<u> </u>							Init	tial	Date
_		weekly blood s					(1)			
				ted, prescribe on	main prescri	ption chart	: (but			
				according to dose	titration, vali	dity of bloo	bd			
	is the mo	st frequent), or	more often	if any parameters						
	or more f side effec electronic	requently if pati- cts they have no c patient record.	ent has any ot been info	issues. Alert med	lical staff if a	ny change	e in			
	• +	lypersalivation								
	• •	locturnal enures	sis							
	• •	lausea								
		-								
	Arrange (wards	6 monthly script	once stable	e dose is reached	on long stay	or rehabi	litation			
		•			_ipids □					
			-							
	increasin <i>month of</i>	g. Rapid weight treatment) stroi	gain in ear ngly predict	ly treatment (≥5% s long-term weigh	above base	line after 1	1			
	Monitor p	lasma clozapin	e levels if c	linically indicated (see Trust gu	uidance)				
	Check sn	noking status re	gularly and	inform medical st	aff of any ch	anges				
		Sedation Hypersalivation Nocturnal enuresis Nausea Signs of infection nge 6 monthly script once stable dose is reached on long stay or rehabilitation s								

RECORD COMPLETION OF EACH TASK IN THE ELECTRONIC PATIENT RECORD (OR SCAN COMPLETED CHECKLIST) Clozapine: processes for prescribing, dispensing, supply & monitoring

Title	Clozapine: processes for prescribing, dispensing, supply & monitoring				
Approved by	Drug & Therapeutics Committee	27 th May 2021, last amended 22 nd Sept 2022			
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024		



Appendix 2: Clozapine Task Checklist – Community initiation

N.B. Parkinson's disease patients may have CPMS approval for reduced blood & physical health monitoring

Patient Name:	Date of Birth:	NHS No.:
Ward:	Consultant:	CPMS No.:

Note: CPMS = CPMS or equivalent monitoring service (ZTAS or DMS)

-		MMENCEMENT OF CLOZA		eted		
ali √		ior to commencement but no		รเซน	Initial	Date
		commence clozapine with pati equirements(*if off-label use, ensu		n MHA		
		n patient re potential benefits, m c patient record, including inforr		ns		
	Ensure the following te record as a physical he of range:					
	Physical examination	Weight (W)	U&Es			
	Blood pressure	Calculate weight	Lipids			
	Temperature	increase threshold (W x 1.05) =	Prolactin			
	Pulse	Waist circumference	HbA1c			
	Height	ECG	LFTs			
	Baseline FBC taken ar from sample date	nd sent to local Path Lab – this	will only be valid for 10 da	ys		
	Confirm consultant reg	istered with CPMS				
		rtment of intention to commenc y, e.g. monitored dose system	e clozapine and any spec	ial		
	Patient registration for	m completed and sent to CPMS	6 (<u>CPMS@viatris.com</u>)			
		ation and green result from CPI ple so clozapine must commen		or 10		
	Prescribe clozapine on	green titration chart (either sta	ndard or individual)			
	Order initial supply of c	clozapine from pharmacy using	one of the following option	ns:		
	c) send titration chart to dispensary (will be kept in dispensary, copy returned with supply)					
	d) outpatient prescrip	tion				
		or seeing patient daily during ea				
	Set up arrangements f patient.	or collection of clozapine from p	bharmacy and/or delivery t	to		

✓		Initial	Date
	Immediately prior to administration of clozapine assess BP, pulse and temp and record on electronic patient record		
	If all above within normal limits administer clozapine – any abnormalities contact doctor for advice as to whether clozapine can be administered		
	If first dose taken at night no further monitoring required that day		
	If first dose taken during the day BP, pulse, temp to be checked hourly for six hours post dose		

Title Clozapine: processes for prescribing, dispensing, supply & monitoring								
Approved by	Drug & Therapeutics Committee	Date of Approval	27 th May 2021, last amended 22 nd Sept 2022					
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024					



	Enter alert on electronic patient record: Significant medication alert – patient on										
	clozapine Arrange date of next FBC test										
	•										
	Check arrangements are in place for next FBC test and supply of clozapine										
	STEP 3: TITRATION OF CLOZAPINE, DAYS 2 – 14: all must be completed but not necessarily in order listed										
an ✓	all must be completed but not necessarily in order listed										
	 Blood sample obtained for FBC at clozapine clinic or sent to path lab within 10 days of baseline test 										
	Monitor and record BP, pulse, temp at least once daily (ideally 2-6 hours post-dose), with crisis team support as necessary, and inform medical staff if out of range										
	Day 7 &	day 14 – check	weight and	record on electro	nic patient re	ecord					
		onic patient rec	ord each w	effects with patier eek (at clozapine o	clinic or sepa	rate consu					
		Constipation	Sedation	Hypersalivation	Nocturnal enuresis	Nausea	Signs of infection				
	Week 1										
	Week 2										
	Inform medical staff if patient reports an increase in side effects or weight is increasing.										
	Brief assessment of mental state completed including mood, thinking and behaviour										
	Arrange attendance at one-stop clozapine clinic or ensure alternative arrangements are in place for monitoring and supply if one-stop clinic is not accessible										
OT	STEP 4: STABILISATION OF CLOZAPINE THERAPY, DAY 15 ONWARDS:										
1.51	FP 4' 51	ARII ISATION		7ΔΡΙΝΕ ΤΗΕΒΔ	PY DAY 1	5 ONWA	RDS				
51 √	EP 4: 51	ABILISATION	N OF CLO	ZAPINE THERA	PY, DAY 1	5 ONWA	RDS:	Initial	Date		
				r FBC at clozapine			RDS:	Initial	Date		
	Continue	e weekly blood	sampling fo		e clinic or via	a path lab		Initial	Date		
	Continue Arrange Monitor B	e weekly blood further supplies 3P, pulse and to	sampling fo of clozapin emp when t	r FBC at clozapine	e clinic or via ion until stab or more ofter	a path lab le dose is n if any par	reached	Initial	Date		
	Continue Arrange Monitor I are out o Monitor s frequent	e weekly blood further supplies 3P, pulse and to frange – alert i side effects, in p y if patient has e not been infor Constipation Sedation Hypersaliva Nocturnal e Nausea	sampling fo of clozapin emp when b medical stat particular the any issues. rmed about. n tion nuresis	r FBC at clozaping the in line with titrat ploods are taken, o	e clinic or via ion until stab or more ofter s are out of i me bloods a f if any chan	a path lab ile dose is n if any par range re taken, c ge in side	reached ameters or more	Initial	Date		
	Continue Arrange Monitor I are out o Monitor s frequentl they have	e weekly blood further supplies BP, pulse and to f range – alert i side effects, in p y if patient has e not been infor Constipation Sedation Hypersaliva Nocturnal e Nausea Signs of infe	sampling fo of clozapin emp when t medical stat particular the any issues. rmed about. n tion nuresis ection	r FBC at clozaping le in line with titrat bloods are taken, o ff if any parameter ose below every ti Alert medical staf	e clinic or via ion until stab or more ofter 's are out of r me bloods a ff if any chan onic patient r	a path lab ile dose is n if any par range re taken, c ge in side	reached ameters or more	Initial	Date		
	Continue Arrange Monitor E are out o Monitor s frequentl they have Arrange Continue Check w increasin <i>treatmen</i>	e weekly blood further supplies 3P, pulse and to f range – alert i side effects, in p y if patient has e not been infor Constipation Sedation Hypersaliva Nocturnal e Nausea Signs of infe 6 monthly prese e physical health eight weekly – ng. Rapid weigh	sampling fo of clozapin emp when t medical stat particular the any issues. rmed about. n tion nuresis ection cription once n monitoring see thresho t gain in eau licts long-te	r FBC at clozapine le in line with titrat ploods are taken, o ff if any parameter ose below every ti Alert medical staf Record on electro	e clinic or via ion until stab or more ofter is are out of r me bloods a fi f any chan onic patient r eached m medical sta o above base	a path lab le dose is n if any par range re taken, o ge in side record.	reached ameters or more effects ht is 1 month of	Initial	Date		
	Continue Arrange Monitor E are out o Monitor s frequentl they have Arrange Continue Check w increasin treatmen preventa	e weekly blood further supplies BP, pulse and to frange – alert i side effects, in p y if patient has e not been infor Constipation Sedation Hypersaliva Nocturnal e Nausea Signs of infe 6 monthly prese e physical health eight weekly – ng. Rapid weigh it) strongly pred	sampling fo of clozapin emp when to medical stat particular the any issues. rmed about. n tion nuresis ection cription once n monitoring see thresho t gain in ea licts long-ten I measures	r FBC at clozapine ie in line with titrat ploods are taken, o ff if any parameter ose below every ti Alert medical staf . Record on electro g as per guidelines pld in step 1; inforr rly treatment (≥5% rm weight gain & s	e clinic or via ion until stab or more ofter is are out of r me bloods a fi f any chan onic patient r eached m medical sta o above base	a path lab le dose is n if any par range re taken, c ge in side record.	reached ameters or more effects ht is 1 month of	Initial	Date		
	Continue Arrange Monitor E are out o Monitor s frequenti they have Arrange Continue Check w increasin treatmen preventa At week	e weekly blood further supplies 3P, pulse and to frange – alert i side effects, in p y if patient has e not been infor Constipation Sedation Hypersaliva Nocturnal e Nausea Signs of infe 6 monthly press physical health eight weekly – ng. Rapid weigh tive or remedia	sampling fo of clozapin emp when k medical stat particular the any issues. rmed about. n tion nuresis ection cription oncon see thresho t gain in ea. licts long-tei I measures ck: ECG	r FBC at clozapine ie in line with titrat ploods are taken, o ff if any parameter ose below every ti Alert medical staf . Record on electro g as per guidelines pld in step 1; inforr rly treatment (≥5% rm weight gain & s	e clinic or via ion until stab or more ofter s are out of r me bloods a f if any chan onic patient r eached m medical sta should promp Lipids	a path lab le dose is n if any par range re taken, c ge in side record. aff if weigh eline after ot consider	reached ameters or more effects ht is 1 month of	Initial	Date		
	Continue Arrange Monitor E are out o Monitor s frequenti they have Arrange Continue Check w increasin treatmen preventa At week Monitor p	e weekly blood further supplies 3P, pulse and to frange – alert i side effects, in p y if patient has e not been infor Constipation Sedation Hypersaliva Nocturnal e Nausea Signs of infe 6 monthly prese physical health eight weekly – ng. Rapid weigh tive or remedia 12 repeat / che plasma clozapir moking status re	sampling fo of clozapin emp when k medical stat particular the any issues. rmed about. n tion nuresis ection cription oncon see thresho t gain in ea. licts long-tei I measures ck: ECG ne levels if c egularly and	r FBC at clozapine le in line with titrat ploods are taken, o ff if any parameter ose below every ti Alert medical staf Record on electro g as per guidelines old in step 1; inforr rly treatment (≥5% rm weight gain & s	e clinic or via ion until stab or more ofter s are out of r me bloods a f if any chan onic patient r eached m medical sta should promp Lipids (see Trust g taff of any ch	a path lab le dose is n if any par range re taken, c ge in side record. aff if weigh eline after ot consider uidance) nanges	reached rameters or more effects ht is 1 month of ration of	Initial	Date		

RECORD COMPLETION OF EACH TASK IN THE ELECTRONIC PATIENT RECORD (OR SCAN COMPLETED CHECKLIST)										
Title Clozapine: processes for prescribing, dispensing, supply & monitoring										
Approved by	Drug & Therapeutics Committee	Date of Approval	27 th May 2021, last amended 22 nd Sept 2022							
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024							



Appendix 3: Standard clozapine prescription

C	LOZAPINE AND CO-M	NEDS PRESC	RIPTION F	ORM		Patie	nt name:			-				
	NB. ONLY TO BE USE		NE PATIENTS			⊕ ^{Bloc}	d test due w	eek:			Dis	pensing	week:	
Sumame:		DOB:					Date of Dispensing	100mg Tabs	25mg Tabs	Dispensed by	Checked by	Clinic date	Date of Blood Test	Resu Statu (G/A/
Forename(s):	NHS no:				1		Disp	Disp					(G/A	
Address:						2								
Team base/clinic:	Team EM				3									
Consultant:		CPMS No				4								
Lead professional:		EPR No.:				5								
Allergies (drug & nature	-)-	Constring a	tatus (dalata a			6								
Allergies (drug & nature	=).		tatus (delete a			7								
		Non-smol	ker Sm	oker	Ex-smoker	8								
						9		1						
Blood frequency	(delete as appropriate)	Weekly	2-week	ly 4-w	eekly	10							1	
Dispensing frequency	(delete as appropriate,	Weekly	2-week	ly 4-w	eekly	11							1	
Method of collection	(delete as appropriate)			Other:		12								
Compliance aid Weekly packs	(delete as appropriate) (delete as appropriate)		s – expiry dat	te:		13								
Weekly packs	(delete as appropriate)	NO TE	5			14								
Drug			ose	-	Stop Date	15								
(amend brand name i	If necessary) 08:00	12:00	18:00	22:00	stop Date	16								
Clozapine (Clozaril)						17								
						18								
						19								
						20								
						21							1	
						22								
					1	23							1	
NB: Prescr	nption valid for 6 months f	rom first dispens	ang or until d	ose is changed	1	24								
					Date	25								
	Signature	Nam	e (print)	-	Jate	26								
Presoriber:						27								
Pharmaolet: (Professional check):						28							1	
						29							1	
Clozapine on SCR?		Yes	No			30							1	
Co-meds on SCR?							•	•	•	•	•	•		
Co-measion SCR?		Yes	No	N/A										

Title	Clozapine: processes for prescribing, dispensing, supply & monitoring							
Approved by	Drug & Therapeutics Committee	Date of Approval	27 th May 2021, last amended 22 nd Sept 2022					
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024					



Appendix 4: Prescription tracker example

Patient's Name	PARIS ID	NHS No.	D.O.B	Consultant	Clozapine Dose	Total Clozapine Dose	Augmentation	Co-Meds	Type of Prescription	Dispensing Type	Type of Change	Notificati on Date	Date Rx Sent to Consultant/Presc riber/Secretary	Method Rx Sent	Completed By	Review Date	Clozapine on SCR	Issues with SCR	Notes
Patient 1				Psyc 1	175mg DN	175mg			Clozapine Only		6 Month Pleview		13/07/20	Printed Copy	MC & MW	11012021	No	No	Email sent to GP to update SCR
Patient 2				Psyc 1	2pm, 175mg 6pm, 22fma 10nm	750mg	Other	Lorazepam Img PRN, Trifluoperazine 5-10mg PRN	Clozapine Only		6 Month Review		14/07/20	Printed Copy	MC & MW	12/01/2021	Yes	No	
Patient 3				Psyc 1	100mg SIX times a day, 50mg DN	650mg	Other	Lorazepam 1mg PRN, Sertraline 50mg DM	Clozapine Only	Weekly Medi Pack	6 Month Review		15/07/20	Printed Copy	MC & MW	13/01/2021	Yes	Yes	On Citalopram on SCR
Patient 4				Psyc 1	75mg DM, 100mg CN	175mg	Aripiprazole s 5mg	Anipiprazole 5mg DM	Clozapine Only		6 Month Review		16/07/20	Printed Copy	ME & MW	14/01/2021	Yes	No	
Palient 5				Psyc1	150mg CM, 100mg 6pm, 325mg CN	575mg	Other	Amitriptyline 25mg DN, Diazepam 2mg BD	Clozapine Only		6 Month Review		17/07/20	Printed Copy	MC & MW	15/01/2021	Yes	No	
Patient 6				Paye 1	100mg OM, 275mg ON	375mg	Other	Sertraline 200mg DM	Clozapine Only		6 Month Review		19/07/20	Printed Copy	ME & MW	16/01/2021	Yes	No	
Palient 7				Psyc 1	400mg CN	400mg			Clozapine Only	Weekly Medi Pack	6 Month Review		19/07/20	Printed Copy	ME & MW	17/01/2021	Yes	Yes	On Clonazepam on SCR
Patient 54				Paye 3	100mg CM, 125mg CN	225mg			Clozapine Only		Dose Reduced		14/09/20	Printed Copy	MC & MW	15/03/2021	Yes	No	
Palient 55				Psyc 3	100mg DM, 325mg DN	425mg		Depakote 500mg BD	Clozapine Only		Site Change		19/09/20	Printed Copy	ME & MW	19/03/2021	Yes	No	
Patient 56				Psyc 3	50mg CM, 500mg CN	550mg			Clozapine Only		Dose Increased		18/09/20	Printed Copy	MC & MW	19/03/2021	Yes	No	
alient 57				Psyc 3	100mg DM, 250mg DN	350mg			Clozapine Only		New Patient		29/09/20	Printed Copy	MC & MW	29/03/2021	Yes	No	
Patient 58				Psyc 3	200mg CM, 300mg CN	500mg			Clozapine Only		Dose Increased		02/10/20	Printed Copy	MC & MW	02/04/2021	Yes	No	
Palient 59				Psyc 3	150mg DM, 300mg ON	450mg			Clozapine Only		Dose Reduced		06/10/20	Printed Copy	ME & MW	06/04/2021	Yes	No	
Patient 60				Paye 3	250mg CM, 325mg CN	575mg	Other	Sertraline 150mg OM	Clozapine and Menta Health Co-Meds	Weekly Medi Pack	Mental Health Co- Meds		27/10/20	Printed Copy	MC & MW	27/04/2021	Yes	No	
atient 61				Psyc 3	150mg 12pm. 200mg DN	350mg			Clozapine Only		Dose Reduced		27/10/20	Printed Copy	ME & MW	27/04/2021	Yes	No	
Palient 62				Psyc 3	150mg DM, 400mg CN	550mg			Clozapine Only		Dose Increased		27/10/20	Printed Copy	ME & MW	27/04/2021	Yes	No	
Palient 63				Paye 3	250mg CN	250mg			Clozapine Only		Dose Increased		25/11/20	Printed Copy	MC & MW	26/05/2021	Yes	No	
Patient 64				Psyc 3	25mg CN	25mg			Clozapine Only		Dose Increased		29/12/20	Printed Copy	ME & MW	29/06/2021	No	No	
Palient 65				Psyc 3	100mg CM, 225mg CN	325mg			Clozapine Only	Weekly Medi Pack	Dose Increased		29/12/20	Printed Copy	ME & MW	29/06/2021	Yes	No	
Patient 66				Psyc 3	200mg CN	200mg	Amisulpride	Amisuipride 400mg Lim, Sodium Valproate MR 200mg DM & 400mg DN Machine M, 150ms DM	Clozapine Only		Dose Reduced		29/12/20	Printed Copy	MC & MW	29/06/2021	Yes	No	
Palient 67				Psyc 3	300mg CM, 300mg CN	600mg		CBI Handbains VI Billion CBJ	Clozapine Only	Weekly Medi Pack	Dose Reduced		30/12/20	Printed Copy	ME & MW	30/06/2021	Yes	No	
Palient 68				Psyc 3	75mg CM, 400mg CN	475mg			Clozapine Only		6 Month Review		09/01/21	Printed Copy	MC & MW	09/07/2021	Yes	No	
Palient 69				Psyc 3	100mg OM, 225mg ON	325mg	Sulpiride	Sulpiride 200mg BD	Clozapine and Menta Health Co-Meds		6 Month Review		09/01/21	Printed Copy	MC & MW	09/07/2021	Yes	No	
atient 70				Psyc 3	275mg ON	275mg	Other	Sodium Valproate 400mg BD	Clozapine and Menta Health Co-Meds		6 Month Review		09/01/21	Printed Copy	MC & MW	09/07/2021	Yes	No	
Patient 71				Psyc 3	125mg CIM, 150mg CIN	275mg		Veniaraxine 337.5mg LU, Sodium Valproate 400mg BD, Amisulpride 750mp/80-2016-2016-2016	Clozapine Only		6 Month Review		08/01/21	Printed Copy	ME & MW	09/07/2021	Yes	No	Lots of medis

Tracker used in Harrogate – available <u>here</u>. Formatting of "review date" column calculates an expiry date with RAG colour-coding to facilitate nonbatch processing of prescriptions, spreading the new prescription task through the year.

Title	Clozapine: processes for prescribing, dispensing, supply & monitoring							
Approved by	Drug & Therapeutics Committee	Date of Approval	27 th May 2021, last amended 22 nd Sept 2022					
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024					



Appendix 5: Dose change communication form

Clozapine / co-meds dose change request

Email completed sheet to usual supplying dispensary:

Foss Park (York): tewv.pharmacyyork@nhs.net

Roseberry Park (Middlesbrough): tewv.pharmacytees@nhs.net

West Park (Darlington): tewv.pharmacycdd@nhs.net

Patient Name:	
PARIS number:	
Date of birth:	
CPMS number (if known) or other relevant monitoring service if not taking Clozaril	
Current dose of clozapine/co-meds	
NEW DOSE REQUIRED	
Urgency of change	immediately
(tick)	within the next 7 days (on usual clinic day)
	next clinic appointment
Reason for change	

Please see PHARMACY case note from last clinic for current dose / date of next clinic appointment

Title	Clozapine: processes for prescribing, dispensing, supply & monitoring			
Approved by	Drug & Therapeutics Committee Date of Approval 27 th May 2021, last amended 22 nd Sept 202			
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024	





Appendix 6: Medication log

Name:								
Date put into cupboard	Quantity In (packs)	Date removed from cupboard	Quantity Out (packs)	Remaining quantity (packs)	Signed Out By: (staff print name)	Signed Out By: (staff signature)	Delivered ∶(✔)	Patient/Proxy if collected

Title	Clozapine: processes for prescribing, dispensing, supply & monitoring			
Approved by	Drug & Therapeutics Committee Date of Approval 27 th May 2021, last amended 22 nd Sept 2022			
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024	



Appendix 7: Quarantine sticker, cupboard notice & log sheet



QUARANTINED **CLOZAPINE**

DO NOT GIVE TO PATIENT WITHOUT AUTHORISATION FROM PHARMACIST

QUARANTINED CLOZAPINE

NOT TO BE RELEASED WITHOUT AUTHORISATION FROM PHARMACY

Title	Clozapine: processes for prescribing, dispensing, supply & monitoring			
Approved by	Drug & Therapeutics Committee Date of Approval 27 th May 2021, last amended 22 nd Sept 2022			
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024	



Quarantined Clozapine Log Sheet

Date put into cupboard	Patient ID	Date removed from cupboard	Nurse Signature	Nurse name	Name of Pharmacy staff authorising release	Patient Signature

Title	Clozapine: processes for prescribing, dispensing, supply & monitoring			
Approved by	Drug & Therapeutics Committee Date of Approval 27 th May 2021, last amended 22 nd Sept 2022			
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024	



Appendix 8: Supplying clozapine to a patient outside of one-stop clinic

All staff handing out clozapine, whether a nurse or member of the pharmacy team should check the following three questions with the patient before handing over clozapine medication:

- 1. what dose of clozapine you are taking?
- 2. Has anyone told you to change the dose of clozapine you take since you last collected it?
- 3. Have you missed any doses of clozapine recently?

If the patient states yes to question 2, and "more than one dose" to question 3 above then refer to the relevant clozapine clinic for advice before handing supply to the patient.

If any problems are identified these should be recorded on the electronic patient record

Supplies collected from TEWV bases without a clinic and GP practices

Clozapine to be supplied to patients via their CMHT base or GP surgery (pending a GREEN blood result) should be prepared with a collection pro-forma attached (see next page for example, versions for each dispensary are <u>here</u>). The CMHT / GP surgery staff should ask the patient to sign this form, then scan and email it back to the relevant TEWV dispensary. If the medication is not collected by the date indicated, the relevant TEWV dispensary <u>must</u> be notified.

Title	Clozapine: processes for prescribing, dispensing, supply & monitoring			
Approved by	Drug & Therapeutics Committee Date of Approval 27 th May 2021, last amended 22 nd Sept 2022			
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024	



TEWV Pharmacy Department West Park Hospital Edward Pease Way Darlington, DL2 2TS

Please Scan Back to the dispensary at West Park Hospital tewv.pharmacycdd@nhs.net

Tel: 01325 552296

Message – FAO Clozapine Pharmacy Technician				
Clozapine Medication Collection Confirmation				
Patient Name				
Patient Signature///				
Collection Location				
Please scan this form to the TEWV Trust Pharmacy team once the patient has signed, dated and collected their medication from your practice				
Please contact the Trust Pharmacy Team on 01325 552296 if medication has not been collected by the date detailed below				

Medication should be collected by -

Confidentiality Statement: The information contained in this document is legally privileged and confidential information intended for the above named only. If you are NOT the intended recipient you are hereby notified that any dissemination, distribution or copy of this document is strictly prohibited. If this has come to you in error, please immediately notify us by telephoning the above number and return the original copy to us by post to the above address. The cost will be reimbursed to you.

Title	Clozapine: processes for prescribing, dispensing, supply & monitoring			
Approved by	Drug & Therapeutics Committee Date of Approval 27 th May 2021, last amended 22 nd Sept 2022			
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024	





Appendix 9: Counselling checklist for clozapine patients

For use by Pharmacy Technicians at One Stop Clozapine Clinics, or by nurse in clinic without pharmacy presence

Frequency	Issue	Question	Referral / Action criteria
At every clinic	Compliance	What is your current dose?	Dose not as per script / prepared supply
contact		Have you missed any doses?	 More than odd doses missed; >48 hours since last dose taken
		Have you taken any extra doses?	Any extra doses taken
		 Have you any clozapine tablets left at home? 	More than required until end of current week (excluding any
		 How many clozapine tablets do you have left at home? 	extra supply for business continuity)
		• Are you managing with how clozapine is supplied to you?	Request for different method of supply, e.g. compliance aid
		Reminder – rotate supplies so they don't expire	
	Side effects	 Do you have any side effects? 	Constipation if no treatment has commenced or not resolving with
		In particular:	treatment
		Constipation?	Diarrhoea
		• Diarrhoea? – may be a sign of overflow from constipation	Worsening treated hypersalivation; untreated hypersalivation
		Hypersalivation?	which has not already been discussed with a prescriber
		Any other physical symptoms that you don't usually have	Any other physical health symptoms not normally experienced
		(e.g. sore throat, flu like symptoms, palpitations)	
	Smoking status	Do you smoke cigarettes?	• Any change in smoking status, including switch from cigarettes to
		Have you recently stopped smoking cigarettes, or cut down	e-cigarette/vaping or vice versa
		a lot?	 Request for support with smoking cessation
		Have you recently started smoking cigarettes or increased	
		the amount you smoke a lot?	
	Alcohol /	 Do you drink any alcohol at all? 	 Regular alcohol use >2 units daily
	substance	If so, how much do you drink?	Increase in alcohol or caffeine use
	misuse	 Do you use any other substances? 	Binge drinking *
		Do you drink excessive caffeine-containing drinks?	Any substance use not already documented
	Medication	 Any change in medication prescribed for you by GP or 	Any change in psychotropic medication
	changes	secondary care?	Any new medication which interacts with clozapine or co-meds
		 Do you take any medicines you buy OTC, and have you 	(check BNF)
		changed the doses of any of these?	Any OTC medication taken regularly but not already recorded
Every 6 months	Compliance (if	Do you still need your medication supplied in a compliance	
(for new	medication	aid?	
prescription)	supplied in	Is there something else that would help you take your	
	medipack	medication, e.g. app, reminder chart?	

*Binge drinking defined as: In a short space of time (e.g. 1hr) drinking more than 8 units for males or 3 units for female, or drinking to get drunk (Ref http://www.nhs.uk/Livewell/alcohol/Pages/Bingedrinking.aspx)

Title	Clozapine: processes for prescribing, dispensing, supply & monitoring			
Approved by	Drug & Therapeutics Committee Date of Approval 27 th May 2021, last amended 22 nd Sept 2022			
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024	





Appendix 10: Template entries for electronic patient record

- → Staff should make appropriate entries for the actions they have taken. Any specific issues should be noted.
- → The entry will vary according to whether the full supply is given to the patient or just one weeks supply and whether co meds are also given to the patient.
- → The following are suggested case note entries for the blood results and actions taken in one stop clinics:

For Green Result:

Bloods analysed on POCHi machine for 'X weekly' clozapine FBC monitoring, GREEN result obtained. 'X' week(s) supply of clozapine given to patient. (Further 'x' weeks supply transferred to medication cupboard for weekly issue).

For Amber Result:

Bloods analysed on POCHi machine for 'X weekly' clozapine FBC monitoring, AMBER result obtained. Patient now requires twice weekly blood monitoring until green result achieved. 'X' week(s) supply of clozapine given to patient. (Further 'x' weeks supply transferred to medication cupboard for weekly issues).

For Red Result:

Bloods analysed on POCHi machine for clozapine FBC monitoring, RED result obtained. NO clozapine given to patient. Patient advised to STOP CLOZAPINE IMMEDIATELY. Advice taken from CPMS re. further blood monitoring

For retrieving blood results from WebICE and entering on CPMS - example from York:

X got a GREEN clozapine blood result on xx/yy/zzzz. Blood results given over the phone from YDH path lab and inputted onto CPMS by myself

Eosinophils - x Platelets x WBC x Neutrophils x Medication issued - 4 weeks Clozapine xxx mg ON Next bloods due in 4 weeks, xx/xx/xxxx

Medication will go on Thursday transport to Worsley Court XX/YY/ZZZZ for collection

Title	Clozapine: processes for prescribing, dispensing, supply & monitoring		
Approved by Drug & Therapeutics Committee Date of Approval 27 th May 2021, last amen		27 th May 2021, last amended 22 nd Sept 2022	
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024



Appendix 11: Clozapine Task Checklist – Inpatient Admission

Patient Name: DOB: NHS no.:

Note: CPMS = CPMS or equivalent monitoring services (ZTAS or DMS)

ST	STEP 1 – MUST BE COMPLETED BEFORE STEP 2 Ward team / Clinical Pharmacy team				
✓		Initial	Date		
	Confirm brand of clozapine =				
	Confirm current dose =				
	Confirm date & time of last dose taken =				
	(If more than 48 hours since last dose, re-titration will be necessary, do not administer usual dose, see clozapine guidance or contact pharmacy for advice)				
	Confirm date of last FBC: and status: Red / Amber / Green				
	Confirm frequency of FBC monitoring - weekly / 2-weekly / 4 weekly				
	Date next blood test due =				

ST	STEP 2 – MUST NOT BE COMPLETED UNTIL STEP 1 COMPLETE Prescriber		
✓		Initial	Date
	Prescribe clozapine on prescription & administration chart:		
	(ONLY if dose can be verified, it is less than 48 hours since last dose was taken AND patient has a valid green result)		

ST	STEP 3 – Clinical pharmacy team / Prescriber			
~			Initial	Date
	Patient's own supply of clozapine brought in on admission? if yes then	YES / NO		
	Is Patient's own supply suitable for use on ward? if no then	YES / NO		
	Order new supply of clozapine from relevant dispensary			

ST	EP 4 – Ward team / Clinical pharmacy team / clozapine team		
✓		Initial	Date
	Confirm usual dispensary and notify of admission (if not already aware at step 1-3)		
	Dispensary – suspend 6-month prescription & notify clinic pharmacy technician		
	Inform CMHT of admission		
	Name of person informed: Date:		
	Clinical pharmacy team - inform <u>CPMS@viatris.com</u> of any changes to consultant / dispensing pharmacy / monitoring clinic / laboratory etc.		
	Check that any supplies held by CMHT / Clozapine clinic have been returned to dispensing pharmacy		
	Update usual clinic eVCB / paper records		
	Update in-patient eVCB with dates of next FBC test		
	Ensure regular monitoring (weekly on acute admission wards, in line with FBC monitoring on long-stay wards) of physical health side-effects, e.g. constipation, using GASS for clozapine		

RECORD COMPLETION OF EACH TASK IN THE ELECTRONIC PATIENT RECORD (OR SCAN COMPLETED CHECKLIST)

Title	Clozapine: processes for prescribing, dispensing, supply & monitoring		
Approved by	Drug & Therapeutics Committee Date of Approval 27 th May 2021, last amended 22 nd S		
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024



Appendix 12: Clozapine Task Checklist - Inpatient Discharge / Transfer

Patient Name: DOB: NHS no.:

Planned discharge date: Ward:CPMS no.:

Note: CPMS = CPMS or equivalent monitoring services (ZTAS or DMS)

ST	STEP 1 – Discharge formulation meeting. Ward team / Clinical Pharmacy team if possible		
✓		Initial	Date
	Current dose: STABLE / TITRATING		
	If still titrating, make arrangements for continued monitoring of physical health, and review of dose by community consultant		
	Assess need for compliance aid: REQUIRED – short-term or long-term?		
	NOT REQUIRED		
	Is prescription of Co-meds required in community?: REQUIRED		
	NOT REQD (transfer to GP)		
	Identify any information needs for patient / carer regarding clozapine, e.g. PIL, reminder chart, MAR chart		
	Bloods samples taken on ward for FBC if due		
	Sufficient discharge medication ordered to correlate with next clozapine clinic and blood validity		
	Appointment made at relevant monitoring clinic and given to patient:		
	Clinic: Time:		

STEP 2 – Prior to discharge Ward team

√		Initial	Date
	Inform clinical pharmacy team of intended discharge date		
	Inform in-patient dispensary of intended discharge date		
	Inform relevant one-stop clozapine clinic of intended discharge date		
	Inform CMHT of intended discharge date and clinic appointment details		
	Name of person informed:		
	Six month prescription prepared for signing and sent to consultant by agreed route		
	(only for patients on a stable dose, including dose adjustment from re- commencement of smoking)		
	Add details of prescription to clozapine tracker		

ST	STEP 3 – After discharge Pharmacy team			
✓		Initial	Date	
	Receiving Clinical pharmacy team inform <u>CPMS@viatris.com</u> of any change in consultant, dispensing pharmacy, monitoring clinic			
	Update eVCB / paper records as needed			

RECORD COMPLETION OF EACH TASK IN THE ELECTRONIC PATIENT RECORD (OR SCAN COMPLETED CHECKLIST)

Title	Clozapine: processes for prescribing, dispensing, supply & monitoring		
Approved by	Drug & Therapeutics Committee Date of Approval 27 th May 2021, last amended 22		
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024



Appendix 13: Clozapine Annual Review Checklist

(community patients only)

Patient Name:	. DOB:	NHS no.:
---------------	--------	----------

CMHT: CPMS (or equiv) no.:

Responsibility for all steps: prescriber; responsible consultant

ST	STEP 1 – Routine Monitoring (as per <u>TEWV Psychotropic Medication Monitoring Guide</u>):				
✓	Parameter	Result / comment			
	Blood Pressure				
	Pulse				
	Weight				
	Waist Circumference				
	Lipids				
	HbA1c				
	ECG (if c/v risk or otherwise clinically indicated)				
	General physical examination				

ST	EP 2 – Monitoring of side effects and efficacy:	Action / comment	
	s an appropriate ratings scale been used to assess symptoms, e.g. RS, in past 12 months?	YES / NO	
	he patient adherent to the medication regimen? Are any co-meds still uired?	YES / NO	
	s an appropriate ratings scale been used to assess side effects, e.g. SS for clozapine, SESCAM, LUNSERS, in past 12 months?	YES / NO	
✓	Check for:	Present / changed?	
	Hypersalivation?	YES / NO	
	Constipation?	YES / NO	
	Sedation?	YES / NO	
	Seizures? if no, and taking valproate, consider checking levels & stopping	YES / NO	
	Changes to smoking status?	YES / NO	
	Changes to overall physical health?	YES / NO	
	Any indication for checking clozapine levels? (as per "Clozapine and the Role of Therapeutic Monitoring guidance")	YES / NO	

ST	STEP 3 – Documentation and follow up:					
✓						
	Review plasma clozapine level (if measured/clinically appropriate) and make any dose adjustments					
	Ensure all monitoring information is recorded on the electronic patient record					
	Ensure any dose changes are clearly communicated to the relevant dispensary					

Ensure any dose changes are clearly communicated to the relevant dispensary Ensure as part of routine communication that a copy of this checklist is sent to the patient's GP, or GP is notified that clozapine and/or any co-meds have been discontinued.

STEP 4 – Current prescription (for clozapine + co-meds prescribed by TEWV; please ensure these are included in the primary care medication record):				
Drug Dose				
Clozapine				

Review completed by: On (date): Tel:

RECORD DETAILS IN THE ELECTRONIC PATIENT RECORD (OR SCAN COMPLETED CHECKLIST)

Title	Clozapine: processes for prescribing, dispensing, supply & monitoring			
Approved by	Drug & Therapeutics Committee	Date of Approval	27 th May 2021, last amended 22 nd Sept 2022	
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024	



Appendix 14: Template eVCB

Week 1	Next Due Date				CI	ozapine Clinic	C		Pha	macy	CII	nic	Released	Dek	ayed		с	are Co-Ordinator	r	
Clinic Date	Appointment Time	Patient	Speciality	Consultant	CPMS No:	Paris ID	Frequency	Dose	Dispensed	ciozapine Quarantined	Attended	Blood Status	ciozapine Released	Released (Pharmacist's Initialo)	Date	Name	Team	Telephone No:	contacted by (initials)	Date and Time

Title	Clozapine: processes for prescribing, dispensing, supply & monitoring			
Approved by	Drug & Therapeutics Committee	Date of Approval	27 th May 2021, last amended 22 nd Sept 2022	
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024	




Appendix 15: Managing Clozapine Overdose

Protocol Number

PHARM-0146-v1.4

The information below is not intended to be a definitive treatment strategy, but a suggested approach for clinicians. It is based on previous successful experience. Each case should, of course, be considered individually. This information is provided for healthcare professionals and should not be used as a patient information leaflet. If notified of a potential overdose in the community, the importance of attending A&E should be reiterated and followed up to ensure the patient has been reviewed.



Date of Review

1st June 2024



Information for TEWV Clinicians

Background	Signs and symptoms of clozapine overdose	Reporting of side effects	Follow up
 Patients with treatment-resistant schizophrenia have a higher incidence of suicide compared to the general population². Both intentional and accidental overdoses have been reported with clozapine. As noted in the SmPC, mortality associated with clozapine overdose is about 12%¹. Most of the fatalities reported were associated with cardiac failure or pneumonia caused by aspiration and occurred at doses > 2000mg¹. In a few adult individuals, primarily those not previously exposed to clozapine, the ingestion of doses as low as 400mg led to life-threatening comatose conditions and, in one case, to death^{1,2}. Seizures have been reported to occur in patients with plasma clozapine levels above 1 mg/L following overdose.⁴ 	 All of the side-effects associated with clozapine at therapeutic dose may be seen following overdose except those seen with long-term therapy only, e.g. constipation, weight gain and agranulocytosis³. In addition, altered respiratory function and aspiration may be observed and these are seldom seen at therapeutic doses. Pulmonary oedema is not a recognised side-effect but has occurred following overdose³. The central nervous, cardiovascular and respiratory systems are most commonly affected following acute overdose. The signs and symptoms listed in the SmPC are stated above. There is a risk of neuroleptic malignant syndrome Delayed reactions may be seen, including the late occurrence or recurrence of cardiac arrythmias³. 	Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the product. Healthcare professionals are asked to report any suspected adverse reactions via the yellow card system: www.mhra.gov.uk/yellowc ard	 Clozapine remains the antipsychotic of choice for schizophrenia patients with a history of suicidality. Overdose is not a reason to discontinue clozapine treatment, but to institute measures (e.g. restricted supplies) to minimise recurrence. The patient needs to be reviewed with a view to ongoing treatment, overdose risk and quantities to prescribe / supply. Consideration needs to be made as to any supplies at home and whether these need to be returned to pharmacy for disposal. A plan for ongoing treatment doses and blood monitoring needs to be carefully made, discussed with the patient and clearly documented in the patient's electronic record. Refer to the information elsewhere in this document for guidance on action to take following a break in treatment, e.g. notifying and re-registration with CPMS, re-titration

Title	Clozapine: processes for prescribing, dispensing, supply & monitoring		
Approved by	Drug & Therapeutics Committee	Date of Approval	27 th May 2021, last amended 22 nd Sept 2022
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024



Information for clinicians in acute hospitals

Clozapine overdose	Signs and Symptoms	Treatment
The Summary of Product Characteristics (SmPC) for clozapine ¹ states: In cases of acute intentional or accidental clozapine overdose for which information on the outcome is available, mortality to date is about 12%. Most of the fatalities were associated with	Drowsiness, lethargy, areflexia, coma, confusion, hallucinations, agitation, delirium, extrapyramidal symptoms, hyperreflexia, convulsions; hypersalivation, mydriasis, blurred vision, thermolability; hypotension, collapse, tachycardia, cardiac arrhythmias; aspiration pneumonia, dyspnoea, respiratory depression or failure.	 Consult Toxbase <u>https://www.toxbase.org/</u> There are no specific antidotes for clozapine. Gastric lavage and/or administration of activated charcoal within the first 6 hours after the ingestion of the drug. Peritoneal dialysis and haemodialysis are unlikely to be effective. Symptomatic treatment under continuous cardiac monitoring, surveillance of respiration, monitoring of electrolytes and acid-base balance.
cardiac failure or pneumonia caused by aspiration and occurred at doses above 2000	There is a risk of neuroleptic malignant syndrome. ⁵	 The use of adrenaline should be avoided in the treatment of hypotension because of the possibility of a 'reverse adrenaline' effect.
mg.	Due to the high risk of cardiac arrhythmias, consider seeking advice from cardiology	 Close medical supervision is necessary for at least 5 days because of the possibility of delayed reactions, such as cardiac arrhythmias.
	specialists if clinically indicated.	 Any decision to discharge from medical care before this should be carried out by a consultant.
		 Work with the liaison psychiatry team and care co- ordinator prior to discharge for help and advice, and to arrange ongoing treatment and follow up.

References

1. Clozapine Summary of Product Characteristics https://www.medicines.org.uk/emc/product/4411

2. Dev VJ, Krupp P. Adverse Event Profile and Safety of Clozapine. Rev Contemp Pharmacother 1995; 6: 197-208.

3. Le Blaye I et al. Acute Overdosage with Clozapine: a Review of the Available Clinical Experience. Pharm Med 1992; 6: 169-78.

4. Taylor D and Duncan D. The Use of Clozapine Plasma Levels in Optimising therapy. Psych Bulletin 1995; 19: 753-5.


This information was developed from the 2018 Mylan information leaflet CLZ-2018-0126

5. Toxbase- clozapine. <u>www.toxbase.org</u> accessed 30 Sept 2022

Title	Clozapine: processes for prescribing, dispensing, supply & monitoring			
Approved by	Drug & Therapeutics Committee	Date of Approval	27 th May 2021, last amended 22 nd Sept 2022	
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024	




Appendix 16: Summary of roles and responsibilities (inpatient settings)



Title	Clozapine: processes for prescribing, dispensing, supply & monitoring			
Approved by	Drug & Therapeutics Committee	Date of Approval	27 th May 2021, last amended 22 nd Sept 2022	
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024	



Appendix 17: Summary of roles and responsibilities (community settings)



 Obtain plasma level assay results and communicate them to RC / enter on EPR

Title	Clozapine: processes for prescribing, dispensing, supply & monitoring			
Approved by	Drug & Therapeutics Committee	Date of Approval	27 th May 2021, last amended 22 nd Sept 2022	
Protocol Number	PHARM-0146-v1.4	Date of Review	1 st June 2024	